NervGen Pharma Corp. Announces US$15MM Non-Brokered Private Placement
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES Vancouver, Canada. June 30, 2022— NervGen Pharma Corp. (TSX-V: NGEN; OTCQX: NGENF) (“NervGen” the “Company”), a clinical stage biotech company dedicated to developing a first-in-class neuroreparative drug to treat nervous system damage, is pleased to announce that it has entered into […]
The Importance of Dignity in Caregiving
By Codi Darnell June 28, 2022 “Dignity is as essential to human life as water, food, and oxygen.” – Laura Hillenbrand I was 28 years old the first time a care-aid showered me. Just days after surgery, newly paralyzed, and unfamiliar with my own body, it was the first time in my adult life I […]
In Case I Forget – Support for Alzheimer’s Caregivers
By Codi Darnell April 19, 2022 “My vision for In Case I Forget, LLC is to remember for those who forget and to remind caregivers that they are not alone on this journey.” – Ty Lewis Navigating an Alzheimer’s disease diagnosis with a loved one and deciding on the best course of action when it […]
NervGen Pharma Appoints Craig Thompson to the Board of Directors
30 years of industry experience from CEO of Nasdaq-listed biotech to Vice President, Marketing at Pfizer Experience on 16 development stage products, 15 commercial stage products and numerous pre-clinical assets, in both start-up and large pharmaceutical companies Vancouver, Canada. April 13, 2022 – NervGen Pharma Corp. (TSX-V: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a […]
NervGen Pharma Grants Stock Options
Vancouver, Canada. April 6, 2022 – NervGen Pharma Corp. (TSX-V: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a clinical stage biotech company dedicated to developing a first-in-class neuroreparative drug to treat nervous system damage, announced that the Company has granted 376,000 incentive stock options to Employees and Officers exercisable at a price of $2.06 per […]
Life Days: Celebrating the Anniversary of Your Injury
By Codi Darnell April 5, 2022 There are 365 days in a year. Most of them are days that pass by without much thought – the date just a marker to keep us oriented in time. It’s a way to keep track of assignments, registration forms, deadlines and all the other things that make the […]
NervGen Presenting Interim Phase 1 Clinical Trial Data for NVG-291 at the 2022 American Academy of Neurology Annual Meeting
Human subjects now being enrolled in the second cohort of multiple ascending dose portion of the study NVG-291 dose administered in the first cohort is already above the highest corresponding dose found to be efficacious in animal models and is substantially higher than the lower effective doses where dramatic functional improvements were observed Vancouver, […]
NervGen Pharma to Present at 2022 Virtual Growth Conference Presented by Maxim Group / Engages Apaton Finance to Provide Investor Relations Services in Europe
Vancouver, Canada. March 23, 2022 – NervGen Pharma Corp. (TSX-V: NGEN; OTCQX: NGENF) (“NervGen” or the “Company”), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, will be presenting at the 2022 Virtual Growth Conference presented by Maxim Group, being held virtually on March 28-30, 2022. Paul Brennan, NervGen’s President […]
NervGen Pharma Receives Approval from Safety Review Committee to Proceed to Second Cohort in Multiple Ascending Dose Portion of Phase 1 Clinical Trial of NVG-291
The dose of NVG-291 in the first cohort is already above the highest corresponding dose that resulted in dramatic functional improvements in animal models Approval moves NervGen one step closer to Phase 1b/2 efficacy studies in Alzheimer’s disease, multiple sclerosis and spinal cord injury patients later in 2022 NervGen’s proprietary NVG-291, has been demonstrated in […]
NervGen Pharma Reports 2021 Year End Results and Provides Update on Phase 1 Study
Vancouver, Canada. February 28, 2022 – NervGen Pharma Corp. (TSX-V: NGEN; OTCQX: NGENF) (“NervGen” or the “Company”), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, today reported its financial and operational results for the year ended December 31, 2021. “We have continued to make important progress […]